Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Bedwetting Knowledge Centre

Bedwetting, or nocturnal enuresis is defined as intermittent incontinence while sleeping. Applicable to children ≥ 5 years old, wetting episodes of any type that occur in discrete amounts are indicative to nocturnal enuresis.1,2

Due to variations in comorbidity, treatment response and pathogenesis, nocturnal enuresis can be divided into two subgroups – monosymptomatic nocturnal enuresis (MNE) and non-monosymptomatic nocturnal enuresis (NMNE).1,3 Absence of lower urinary tract symptoms or a history of bladder dysfunction is characteristic of MNE, while NMNE is defined as nocturnal enuresis accompanied by daytime urinary symptoms.

Nocturnal enuresis can have a profound impact on the child and their family, lowering a child’s self image, causing behavioural problems and affecting school performance. However, successful treatment improves the mental health of the child and brings practical relief to the family.

Latest News

Phase III trials success for tofacitinib in Plaque Psoriasis- Pfizer

23-Apr-2014

Pfizer Inc. announced top-line ...

ABT 450/r, ABT 267, ABT 333 combination submitted to FDA for Hepatitis C-AbbVie

23-Apr-2014

AbbVie has submitted a New Drug ...

FDA approves Cyramza for Gastric Cancer-Eli Lilly

23-Apr-2014

The FDA has approved Cyramza ...

Phase III trial shows Zonegran for Epilepsy well tolerated in young patients-Eisai

23-Apr-2014

Zonegran (zonisamide), from Eisai, is ...

Valeant Pharma International makes offer for Allergan

23-Apr-2014

Allergan, Inc. confirmed that it has ...

Novartis reorganises product portfolio in deals with GSK and Eli Lilly

23-Apr-2014

Novartis announced that it has reached a ...

Cubist Pharma files combination ceftolozane + tazobactam at FDA for Urinary Tract and Intra-Abdominal Infections.

22-Apr-2014

Cubist Pharmaceuticals, Inc. has ...

Recent Updates

Drugs

Clinical Guidelines

Guidelines for the management of basal cell carcinoma

BSACI guidelines for the management of allergic and non-allergic rhinitis

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Medical Journals

Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy

Magnetoencephalography localizing spike sources of atypical benign partial epilepsy

Critical Care Management of Verapamil and Diltiazem Overdose With a Focus on Vasopressors: A 25-Year Experience at a Single Center

A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability

epgonline.org Social